Ligand ID: NOV Drugbank ID: DB01051(Novobiocin) Indication:For the treatment of infections due to staphylococci and other susceptible organisms |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.72A | 18.75 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.72A | 18.75 | None | ||
![]() | 4URO_A_NOVA2000_1 (DNA GYRASE SUBUNIT B) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 12 | SER E 974ILE E 980ASP D 985ILE D 980ARG E 983 | 1.37A | 18.75 | None | ||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 12 | SER E 974ILE E 980ASP D 985ILE D 980ARG E 983 | 1.34A | 18.75 | None | ||
![]() | 6B89_A_NOVA403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 10 | LEU A1186ALA A1190GLU B1188SER C 937VAL C1189 | 1.66A | 21.52 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 12 | ASN E 978SER E 982ASP E 979ASP E 985ALA F 972 | 1.77A | 20.20 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.71A | 19.49 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.69A | 19.49 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6lzg | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER B 399ASP B 398ASP B 364ALA B 363ILE B 358 | 1.45A | 21.70 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6m0j | SPIKE RECEPTORBINDING DOMAIN (SARS-CoV-2) | 3 / 3 | ASP E 398PHE E 429VAL E 433 | 1.34A | 21.13 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.70A | 19.43 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.68A | 19.43 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6m17 | RECEPTOR BINDINGDOMAIN (SARS-CoV-2) | 5 / 12 | SER E 399ASP E 398ASP E 364ALA E 363ILE E 358 | 1.56A | 22.55 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | PHE D 3ARG D 4LEU D 282ALA D 210 | 1.55A | 19.30 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | PHE B 3ARG B 4LEU B 282ALA B 210 | 1.63A | 19.30 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | PHE C 3ARG C 4LEU C 282ALA C 210 | 1.55A | 19.30 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | PHE B 3ARG B 4LEU B 282ALA B 210 | 1.59A | 19.30 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.61A | 19.30 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | PHE D 3ARG D 4LEU D 282ALA D 210 | 1.56A | 19.30 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.64A | 19.30 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | PHE C 3ARG C 4LEU C 282ALA C 210 | 1.57A | 19.30 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.61A | 19.30 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.63A | 19.30 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 691ASP A 684ALA A 580ILE A 589SER A 759 | 1.80A | 13.48 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6m71 | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 208PHE A 45VAL A 128 | 1.78A | 17.90 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 881ARG A 889ALA A 866GLN A 886 | 1.77A | 14.56 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 209ASP A 218ASP A 211ASP A 92ALA A 195 | 1.55A | 11.62 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 753ARG A 750LEU A 749ALA A 777 | 1.56A | 14.56 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 348ARG A 349LEU A 351ALA A 656 | 1.58A | 14.56 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 348ARG A 349LEU A 351ALA A 656 | 1.61A | 14.56 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6m71 | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 356PHE A 652VAL A 354 | 1.10A | 17.90 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6m71 | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 356PHE A 348VAL A 535 | 1.07A | 17.90 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 753ARG A 750LEU A 749ALA A 702 | 1.55A | 14.56 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | ARG A 569LEU A 576ALA A 580GLN A 570 | 1.74A | 14.56 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6m71 | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 465PHE A 45VAL A 128 | 1.52A | 17.90 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6m71 | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 39PHE A 48VAL A 42 | 1.08A | 17.90 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m71 | NSP12NSP7 (SARS-CoV-2) | 4 / 6 | PHE A 442LEU C 41ALA A 550GLN C 34 | 1.67A | 14.56 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 506LEU A 372ALA A 375GLN A 524 | 1.70A | 14.56 | None | ||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ASN A1074GLU A1072ILE A 714ILE A 712THR A 716 | 1.73A | 10.56 | NAG A1309 (-1.9A)NoneNoneNoneNone | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP B1041PHE C 888VAL C1033 | 1.32A | 15.44 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 7 | ARG B1014LEU C1012ALA C1015GLN C 774GLN B1011 | 1.79A | 11.77 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ASN B 709SER B 708ASP C 796MET C 900ALA C 903 | 1.70A | 9.94 | NAG B1305 (-1.8A)NoneNAG B1305 (-4.3A)NoneNone | ||
![]() | 1AJ6_A_NOVA1_1 (GYRASE) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | ASN A1074GLU A1072ILE A 714ILE A 712THR A 716 | 1.72A | 10.74 | NAG A1309 (-1.9A)NoneNoneNoneNone | ||
![]() | 1KIJ_B_NOVB444_1 (DNA GYRASE SUBUNIT B) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ASN A1074GLU A1072ILE A 714ILE A 712THR A 716 | 1.62A | 15.44 | NAG A1309 (-1.9A)NoneNoneNoneNone | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ASN B1023PRO B 728ASP B 950GLN B 954ILE B1018 | 1.75A | 10.56 | None | ||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6vww | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | GLU A 114ILE A 100PRO A 112ILE A 80SER A 98 | 1.71A | 22.55 | None | ||
![]() | 4URO_A_NOVA2000_1 (DNA GYRASE SUBUNIT B) | 6vww | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | GLU A 114ILE A 100PRO A 112ILE A 80SER A 98 | 1.71A | 22.55 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6vww | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | ILE A 100PRO A 112ALA A 82ILE A 80SER A 98 | 1.64A | 22.55 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6vxs | NSP3 (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 116VAL B 151 | 1.70A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6vxs | NSP3 (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 168VAL B 144 | 1.02A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP B1041PHE C 888VAL C1033 | 1.21A | 15.04 | None | ||
![]() | 1AJ6_A_NOVA1_1 (GYRASE) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | ASN C1074GLU C1072ILE C 714ILE C 712THR C 716 | 1.75A | 11.06 | NAG C1316 (-1.9A)NoneNoneNoneNone | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER A 399ASP A 398ASP A 364ALA A 363ILE A 358 | 1.48A | 9.81 | None | ||
![]() | 1KIJ_A_NOVA400_1 (DNA GYRASE SUBUNIT B) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PRO C 807ASP C 808ILE C 805LYS C 795THR C 874 | 1.45A | 15.04 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER A 205GLU A 191ARG A 34ALA A 288ILE A 285 | 1.43A | 9.81 | None | ||
![]() | 1KIJ_A_NOVA400_1 (DNA GYRASE SUBUNIT B) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PRO A 807ASP A 808ILE A 805LYS A 795THR A 874 | 1.38A | 15.33 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP C1041PHE A 888VAL A1033 | 1.21A | 15.33 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ASN A 234ARG C 355ILE A 231PRO A 230ASP A 228 | 1.73A | 10.54 | NAG A1303 (-1.9A)NoneNoneNoneNone | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w01 | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | PHE B 214LEU B 215ALA B 256GLN B 209 | 1.46A | 21.37 | None | ||
![]() | 1KIJ_A_NOVA400_1 (DNA GYRASE SUBUNIT B) | 6w01 | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | ASP A 79ILE B 116ASP B 79ILE B 108THR B 115 | 1.77A | 22.13 | EDO A 407 (-4.0A)NoneEDO B 404 (-4.0A)NoneNone | ||
![]() | 6B89_A_NOVA403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w01 | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 10 | ALA B 82PRO B 68GLU B 69VAL B 128ARG B 127 | 1.62A | 21.37 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6w02 | NSP3 (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 168VAL A 144 | 1.00A | 18.78 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w37 | PROTEIN 7A (SARS-CoV-2) | 4 / 6 | PHE A 44ARG A 10ARG A 63LEU A 62 | 1.71A | 14.11 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w37 | PROTEIN 7A (SARS-CoV-2) | 4 / 7 | PHE A 44ARG A 10ARG A 63LEU A 62 | 1.67A | 14.11 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 5 / 12 | SER C 399ASP C 398ASP C 364ALA C 363ILE C 358 | 1.36A | 24.62 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6w4h | NSP16 (SARS-CoV-2) | 3 / 3 | ASP A6912PHE A6868VAL A6916 | 1.06A | 24.21 | SAM A7102 (-3.6A)NoneNone | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 3 / 3 | ASP A6912PHE A6868VAL A6916 | 1.06A | SAM A7104 (-3.6A)NoneNone | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.63A | 19.30 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.66A | 19.30 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6w6y | NSP3 (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 116VAL A 151 | 1.80A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6w6y | NSP3 (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 168VAL A 144 | 1.05A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6w6y | NSP3 (SARS-CoV-2) | 3 / 3 | ASP A 145PHE A 168VAL A 16 | 1.67A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | PHE B 116LEU B 93ALA B 124GLN B 118 | 1.77A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6w6y | NSP3 (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 168VAL B 144 | 0.87A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6w75 | NSP16 (SARS-CoV-2) | 3 / 3 | ASP A6912PHE A6868VAL A6916 | 1.04A | 18.44 | SAM A7102 ( 3.5A)NoneNone | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6w75 | NSP16 (SARS-CoV-2) | 3 / 3 | ASP C6912PHE C6868VAL C6916 | 1.04A | 18.44 | SAM C7105 ( 3.5A)NoneNone | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 3 / 3 | ASP A 37PHE A 55VAL A 41 | 1.75A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | PHE A 173LEU A 178ALA A 176GLN A 237 | 1.77A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 7 | ARG B 166LEU B 211ALA B 249GLN B 250 | 1.59A | 20.49 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | PHE C 173LEU C 178ALA C 176GLN C 237 | 1.72A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 7 | ARG A 166LEU A 211ALA A 249GLN A 250 | 1.76A | 20.49 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 7 | ARG C 166LEU C 211ALA C 249GLN C 250 | 1.53A | 20.49 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | PHE B 173LEU B 178ALA B 176GLN B 237 | 1.72A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 7 | PHE B 173LEU B 125ALA B 176GLN B 122 | 1.79A | 20.49 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6wcf | NSP3 (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 116VAL A 151 | 1.79A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6wen | NSP3 (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 168VAL A 144 | 1.20A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6wen | NSP3 (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 116VAL A 151 | 1.79A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6wey | NSP3 (SARS-CoV-2) | 3 / 3 | ASN A 219PHE A 320VAL A 355 | 1.79A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6wey | NSP3 (SARS-CoV-2) | 3 / 3 | ASN A 219PHE A 372VAL A 348 | 1.08A | 18.62 | None | ||
![]() | 1AJ6_A_NOVA1_1 (GYRASE) | 6wiq | NSP8 (SARS-CoV-2) | 5 / 9 | ASN B 100ASP B 99ILE B 107ALA B 110ILE B 106 | 1.65A | 24.76 | None | ||
![]() | 4URO_A_NOVA2000_1 (DNA GYRASE SUBUNIT B) | 6wiq | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.70A | 20.09 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6wiq | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.72A | 20.09 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6wiq | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ALA B 110ILE B 106 | 1.70A | 20.09 | None | ||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6wiq | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.66A | 20.09 | None | ||
![]() | 1KIJ_B_NOVB444_1 (DNA GYRASE SUBUNIT B) | 6wiq | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ILE B 107ASP B 112ILE B 106ARG B 111 | 1.79A | 15.60 | None | ||
![]() | 4URO_B_NOVB2000_1 (DNA GYRASE SUBUNIT B) | 6wiq | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.66A | 20.09 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6wiq | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ARG B 96ALA B 110ILE B 106 | 1.56A | 17.28 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 7 | ARG A 293LEU A 291GLN A 303GLN A 289 | 1.78A | 18.67 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 7 | ARG E 293LEU E 291GLN E 303GLN E 289 | 1.76A | 18.67 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 3 / 3 | ASP C6912PHE C6868VAL C6916 | 1.03A | SAH C7102 (-3.3A)NoneNone | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 3 / 3 | ASP A6912PHE A6868VAL A6916 | 1.04A | SAH A7102 (-3.5A)NoneNone | |||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | ASN B 77SER B 78ASP B 82PRO A 106ALA A 90 | 1.20A | 21.18 | NoneNone ZN B 202 (-2.3A)NoneNone | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | ASN D 77SER D 78ASP D 82PRO C 106ALA C 90 | 1.46A | 21.18 | NoneNone ZN D 202 (-2.7A)NoneNone | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6wkq | NSP16 (SARS-CoV-2) | 3 / 3 | ASP A6912PHE A6868VAL A6916 | 1.05A | SFG A7103 ( 3.3A)NoneNone | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6wkq | NSP16 (SARS-CoV-2) | 3 / 3 | ASP C6912PHE C6868VAL C6916 | 1.05A | SFG C7103 ( 3.4A)NoneNone | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | PHE B 124ARG B 136LEU B 134ALA B 82 | 1.73A | None | |||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | GLU A 114ILE A 100PRO A 112ILE A 80SER A 98 | 1.71A | 22.82 | None | ||
![]() | 4URO_A_NOVA2000_1 (DNA GYRASE SUBUNIT B) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | GLU A 114ILE A 100PRO A 112ILE A 80SER A 98 | 1.71A | 22.82 | None | ||
![]() | 6B89_B_NOVB403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 10 | ALA B 82PRO B 68GLU B 69VAL B 128ARG B 127 | 1.67A | 22.69 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | PHE A 124ARG A 136LEU A 134ALA A 82 | 1.72A | None | |||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | ILE A 100PRO A 112ALA A 82ILE A 80SER A 98 | 1.66A | 22.82 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 7 | PHE B 124ARG B 136LEU B 134ALA B 82 | 1.79A | 22.69 | None | ||
![]() | 4URO_A_NOVA2000_1 (DNA GYRASE SUBUNIT B) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | GLU B 114ILE B 100PRO B 112ILE B 80SER B 98 | 1.75A | 22.82 | None | ||
![]() | 6B89_A_NOVA403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 10 | ALA B 82PRO B 68GLU B 69VAL B 128ARG B 127 | 1.61A | 22.69 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | PHE B 214LEU B 215ALA B 256GLN B 209 | 1.44A | None | |||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | ILE B 100PRO B 112ALA B 82ILE B 80SER B 98 | 1.72A | 22.82 | None | ||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | GLU B 114ILE B 100PRO B 112ILE B 80SER B 98 | 1.76A | 22.82 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | GLU A 114ILE A 100PRO A 112ILE A 80SER A 98 | 1.77A | 22.82 | None | ||
![]() | 6B89_A_NOVA403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 10 | ALA A 82PRO A 68GLU A 69VAL A 128ARG A 127 | 1.63A | 22.69 | NoneNoneEDO A 408 (-3.8A)NoneNone | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | PHE A 214LEU A 215ALA A 256GLN A 209 | 1.47A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 7 | PHE A 124ARG A 136LEU A 134ALA A 82 | 1.77A | 22.69 | None | ||
![]() | 6B89_B_NOVB403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 10 | ALA A 82PRO A 68GLU A 69VAL A 128ARG A 127 | 1.68A | 22.69 | NoneNoneEDO A 408 (-3.8A)NoneNone | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.67A | 19.30 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.64A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 168VAL A 144 | 1.28A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 3 / 3 | ASN D 15PHE D 168VAL D 144 | 1.25A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 3 / 3 | ASP A 145PHE A 168VAL A 16 | 1.61A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 3 / 3 | ASN C 15PHE C 168VAL C 144 | 1.25A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 168VAL B 144 | 1.27A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 3 / 3 | ASP A6912PHE A6868VAL A6916 | 1.07A | SAH A7101 (-3.3A)NoneNone | |||
![]() | 4URO_A_NOVA2000_1 (DNA GYRASE SUBUNIT B) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.69A | 20.09 | None | ||
![]() | 1AJ6_A_NOVA1_1 (GYRASE) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 9 | ASN D 100ASP D 99ILE D 107ALA D 110ILE D 106 | 1.72A | 24.76 | None | ||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 12 | ASN D 100ASP D 99ILE D 107ASP D 112ILE D 106 | 1.71A | 20.09 | None | ||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.66A | 20.09 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.71A | 20.09 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ALA B 110ILE B 106 | 1.71A | 20.09 | None | ||
![]() | 4URO_B_NOVB2000_1 (DNA GYRASE SUBUNIT B) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.66A | 20.09 | None | ||
![]() | 1AJ6_A_NOVA1_1 (GYRASE) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 9 | ASN B 100ASP B 99ILE B 107ALA B 110ILE B 106 | 1.65A | 24.76 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.63A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.65A | 19.30 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 4 / 6 | PHE A 173LEU A 178ALA A 176GLN A 237 | 1.75A | None | |||
![]() | 6B89_A_NOVA403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 10 | LEU A 118HIS A 275ALA A 114GLU A 124VAL A 165 | 1.75A | 21.04 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6xez | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 39PHE A 48VAL A 42 | 1.02A | 18.04 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6xez | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 356PHE A 348VAL A 535 | 1.02A | 18.04 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6y2g | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.34A | 19.30 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6y2g | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.28A | 19.30 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.73A | 18.60 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.72A | 18.60 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.71A | 17.19 | None | ||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.65A | 17.19 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN B 100ILE B 107ALA B 110ILE B 106ARG B 111 | 1.55A | 17.19 | None | ||
![]() | 4URO_B_NOVB2000_1 (DNA GYRASE SUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ASP B 112ILE B 106 | 1.65A | 17.19 | None | ||
![]() | 4URO_B_NOVB2000_1 (DNA GYRASE SUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN B 100ILE B 107ASP B 112ILE B 106ARG B 111 | 1.56A | 17.19 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 101ALA B 110ILE B 106ARG B 111 | 1.68A | 16.67 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN B 100ASP B 99ILE B 107ALA B 110ILE B 106 | 1.71A | 17.19 | None | ||
![]() | 4URO_D_NOVD2000_1 (DNA GYRASE SUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN B 100ILE B 107ASP B 112ILE B 106ARG B 111 | 1.67A | 17.19 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN B 100ILE B 107ASP B 112ILE B 106ARG B 111 | 1.61A | 17.19 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ASN D 100ASP D 101ALA D 110ILE D 106ARG D 111 | 1.79A | 16.67 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP A 398PHE A 347VAL A 341 | 1.67A | None | |||
![]() | 4URO_B_NOVB2000_1 (DNA GYRASE SUBUNIT B) | 6yla | LIGHT CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 5 / 12 | ASN E 388ARG C 60PRO C 65ASP C 88GLN C 85 | 1.80A | 21.72 | None | ||
![]() | 1S14_A_NOVA1300_1 (TOPOISOMERASE IVSUBUNIT B) | 6yla | LIGHT CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 5 / 12 | ASN E 388ASP E 364PRO C 65ASP C 88ARG C 67 | 1.80A | 22.65 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 6yla | LIGHT CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 5 / 12 | ASN A 388ARG L 60PRO L 65ASP L 88GLN L 85 | 1.77A | 21.72 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER A 399ASP A 398ASP A 364ALA A 363ILE A 358 | 1.53A | 22.65 | None | ||
![]() | 4URO_A_NOVA2000_1 (DNA GYRASE SUBUNIT B) | 6yla | LIGHT CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 5 / 12 | ASN E 388ARG C 60PRO C 65ASP C 88GLN C 85 | 1.78A | 21.72 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER E 399ASP E 398ASP E 364ALA E 363ILE E 358 | 1.51A | 22.65 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP E 398PHE E 429VAL E 433 | 1.33A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP A 398PHE A 429VAL A 433 | 1.37A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP E 398PHE E 347VAL E 341 | 1.66A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP E 398PHE E 429VAL E 433 | 1.35A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP E 398PHE E 347VAL E 341 | 1.67A | None | |||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER E 399ASP E 398ASP E 364ALA E 363ILE E 358 | 1.55A | 22.65 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.29A | 19.30 | None CL A 503 (-3.7A)NoneNone | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.30A | None CL A 503 (-3.7A)NoneNone | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP A 398PHE A 347VAL A 341 | 1.66A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP E 398PHE E 347VAL E 341 | 1.66A | None | |||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER E 399ASP E 398ASP E 364ALA E 363ILE E 358 | 1.51A | 23.42 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER A 399ASP A 398ASP A 364ALA A 363ILE A 358 | 1.51A | 23.42 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP A 398PHE A 429VAL A 433 | 1.33A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 3 / 3 | ASP E 398PHE E 429VAL E 433 | 1.32A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.70A | 19.30 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.69A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN D 15PHE D 116VAL D 151 | 1.77A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 116VAL A 151 | 1.78A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 116VAL B 151 | 1.79A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | PHE D 116LEU D 93ALA D 124GLN D 118 | 1.78A | NoneNoneNoneEDO D 201 ( 4.4A) | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASP E 145PHE E 168VAL E 16 | 1.70A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASP B 145PHE B 168VAL B 16 | 1.69A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN E 15PHE E 168VAL E 144 | 1.07A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASP A 145PHE A 168VAL A 16 | 1.69A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 168VAL B 144 | 1.15A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | PHE C 116LEU C 93ALA C 124GLN C 118 | 1.76A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN E 15PHE E 116VAL E 151 | 1.74A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 168VAL A 144 | 1.10A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN C 15PHE C 168VAL C 144 | 1.09A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | PHE A 116LEU A 93ALA A 124GLN A 118 | 1.77A | NoneNoneNoneEDO D 201 ( 4.5A) | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN D 15PHE D 168VAL D 144 | 1.06A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN C 15PHE C 116VAL C 151 | 1.74A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN C 15PHE C 116VAL C 151 | 1.73A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 168VAL B 144 | 1.13A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 116VAL B 151 | 1.77A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN E 15PHE E 116VAL E 151 | 1.73A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 116VAL A 151 | 1.78A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN E 15PHE E 168VAL E 144 | 1.09A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASP E 145PHE E 168VAL E 16 | 1.69A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN D 15PHE D 116VAL D 151 | 1.78A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASP C 145PHE C 168VAL C 16 | 1.65A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 7 | PHE D 116LEU D 93ALA D 124GLN D 118 | 1.67A | 22.83 | NoneNoneNoneEDO A 207 ( 4.7A) | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 168VAL A 144 | 1.13A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASP A 145PHE A 168VAL A 16 | 1.67A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN C 15PHE C 168VAL C 144 | 1.05A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN D 15PHE D 168VAL D 144 | 1.04A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | PHE A 116LEU A 93ALA A 124GLN A 118 | 1.76A | NoneNoneNoneEDO A 202 (-4.6A) | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN C 15PHE C 116VAL C 151 | 1.79A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 116VAL B 151 | 1.78A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN C 15PHE C 168VAL C 144 | 1.14A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | PHE C 116LEU C 93ALA C 124GLN C 118 | 1.79A | NoneNoneNoneEDO A 204 (-4.1A) | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASP A 145PHE A 168VAL A 16 | 1.67A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN B 15PHE B 168VAL B 144 | 0.93A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 168VAL A 144 | 1.08A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASP B 145PHE B 168VAL B 16 | 1.66A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 3 / 3 | ASN A 15PHE A 116VAL A 151 | 1.79A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.69A | 19.30 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.67A | None | |||
![]() | 1S14_A_NOVA1300_1 (TOPOISOMERASE IVSUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 68ASP A 67ARG A 55ASP A 218ARG A 116 | 1.78A | 11.62 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 356PHE A 348VAL A 535 | 1.01A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 753ARG A 750LEU A 749ALA A 777 | 1.30A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 287ARG A 285ARG A 183LEU A 186 | 1.80A | 14.56 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 348ARG A 349LEU A 351ALA A 656 | 1.65A | 14.56 | None | ||
![]() | 1KIJ_B_NOVB444_1 (DNA GYRASE SUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 86ASP A 221ILE A 201ALA A 199THR A 85 | 1.59A | 17.90 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 753ARG A 750LEU A 749ALA A 777 | 1.42A | 14.56 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 691ASP A 684ALA A 580ILE A 589SER A 759 | 1.71A | 13.48 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 881LEU A 869ALA A 866GLN A 875 | 1.71A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 348ARG A 349LEU A 351ALA A 656 | 1.61A | None | |||
![]() | 6B89_B_NOVB403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 5 / 10 | LEU A 708ALA A 46TYR A 728SER A 239VAL A 128 | 1.80A | 14.56 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 68ASP A 67ARG A 55ASP A 218ARG A 116 | 1.76A | 11.62 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 287ARG A 285ARG A 183LEU A 186 | 1.76A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 753ARG A 750LEU A 749ALA A 702 | 1.33A | 14.56 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12NSP8 (SARS-CoV-2) | 4 / 7 | ARG B 80LEU A 372ALA A 375GLN B 73 | 1.76A | 19.23 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 153PHE A 157VAL A 174 | 1.62A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 753ARG A 750LEU A 749ALA A 702 | 1.30A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 100PHE A 7VAL A 72 | 1.60A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 356PHE A 652VAL A 354 | 1.00A | None | |||
![]() | 1AJ6_A_NOVA1_1 (GYRASE) | 7btf | NSP8 (SARS-CoV-2) | 5 / 9 | ASN D 100ASP D 99ILE D 107ALA D 110ILE D 106 | 1.50A | 19.38 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7btf | NSP12NSP8 (SARS-CoV-2) | 3 / 3 | ASP A 517PHE A 368VAL B 83 | 1.67A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 39PHE A 48VAL A 42 | 1.05A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 528ARG A 569ALA A 529GLN A 573 | 1.75A | 14.56 | None | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 465PHE A 45VAL A 128 | 1.50A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7btf | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 208PHE A 45VAL A 128 | 1.77A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.66A | NoneNoneDMS A 404 (-4.9A)None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 7 | PHE A 3ARG A 4LEU A 282ALA A 210 | 1.68A | 19.30 | NoneNoneDMS A 404 (-4.9A)None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 691ASP A 684ALA A 580ILE A 589SER A 759 | 1.77A | 11.45 | None | ||
![]() | 1KIJ_B_NOVB444_1 (DNA GYRASE SUBUNIT B) | 7bv1 | NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 106ASP B 99ILE B 107ALA B 110THR B 123 | 1.73A | 19.39 | None | ||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 7bv1 | NSP8 (SARS-CoV-2) | 5 / 12 | ASN D 100ILE D 107ASP D 112ALA D 110ILE D 106 | 1.48A | 20.16 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 753ARG A 750LEU A 749ALA A 777 | 1.42A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 287ARG A 285ARG A 183LEU A 186 | 1.75A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 348ARG A 279LEU A 351ALA A 656 | 1.76A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 287ARG A 285ARG A 183LEU A 186 | 1.79A | 14.44 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 506LEU A 372ALA A 375GLN A 524 | 1.72A | None | |||
![]() | 1KIJ_B_NOVB444_1 (DNA GYRASE SUBUNIT B) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 86ASP A 221ILE A 201ALA A 199THR A 85 | 1.46A | 17.91 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 348ARG A 349LEU A 351ALA A 656 | 1.74A | 14.44 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 753ARG A 750LEU A 749ALA A 702 | 1.44A | 14.44 | None | ||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 7bv1 | NSP8 (SARS-CoV-2) | 5 / 12 | ASN D 100ASP D 101ASP D 112ALA D 110ILE D 106 | 1.60A | 21.97 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 753ARG A 750LEU A 749ALA A 777 | 1.50A | 14.44 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 7bv1 | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 356PHE A 652VAL A 354 | 1.12A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7bv1 | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 465PHE A 45VAL A 128 | 1.55A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 348ARG A 349LEU A 351ALA A 656 | 1.70A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 7bv1 | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 874PHE A 428VAL A 435 | 1.60A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 753ARG A 750LEU A 749ALA A 702 | 1.44A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 3 / 3 | ASP A 517PHE A 368VAL B 83 | 1.61A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 4 / 7 | PHE A 368LEU A 372GLN A 524GLN B 88 | 1.68A | 14.44 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 7bv1 | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 356PHE A 348VAL A 535 | 1.04A | None | |||
![]() | 4URO_C_NOVC2000_1 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 691ASP A 684ALA A 580ILE A 589SER A 759 | 1.70A | 11.45 | F86 P 102 (-4.2A)None A T 13 ( 3.7A)None U P 20 ( 2.8A) | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 153PHE A 157VAL A 174 | 1.71A | None | |||
![]() | 1S14_B_NOVB2300_1 (TOPOISOMERASE IVSUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 691ASP A 760ASP A 623MET A 626PRO A 627 | 1.77A | 11.62 | F86 P 102 (-4.2A)F86 P 102 ( 3.0A)POP A1003 ( 3.5A)NoneNone | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 506LEU A 372ALA A 375GLN A 524 | 1.78A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 356PHE A 348VAL A 535 | 1.02A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 753ARG A 750LEU A 749ALA A 777 | 1.47A | 14.44 | None | ||
![]() | 1KIJ_A_NOVA400_1 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 92ILE A 86ASP A 221ILE A 201THR A 85 | 1.78A | 17.91 | None | ||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 874PHE A 428VAL A 435 | 1.51A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 4 / 7 | PHE A 368LEU A 372GLN A 524GLN B 88 | 1.75A | 14.44 | None | ||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 753ARG A 750LEU A 749ALA A 702 | 1.39A | 14.44 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 348ARG A 279LEU A 351ALA A 656 | 1.73A | None | |||
![]() | 1KIJ_A_NOVA400_2 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 3 / 3 | ASN A 356PHE A 652VAL A 354 | 1.12A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 348ARG A 279LEU A 351ALA A 656 | 1.75A | 14.44 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 348ARG A 349LEU A 351ALA A 656 | 1.61A | None | |||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 753ARG A 750LEU A 749ALA A 777 | 1.39A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 3 / 3 | ASP A 517PHE A 368VAL B 83 | 1.72A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 465PHE A 45VAL A 128 | 1.57A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 208PHE A 45VAL A 128 | 1.74A | None | |||
![]() | 6B89_B_NOVB403_1 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | PHE A 348ARG A 349LEU A 351ALA A 656 | 1.65A | 14.44 | None | ||
![]() | 6B89_A_NOVA403_2 (LIPOPOLYSACCHARIDEEXPORT SYSTEMATP-BINDING PROTEINLPTB) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | PHE A 753ARG A 750LEU A 749ALA A 702 | 1.41A | None | |||
![]() | 1S14_A_NOVA1300_1 (TOPOISOMERASE IVSUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 691ASP A 760ASP A 623MET A 626PRO A 627 | 1.76A | 11.62 | F86 P 102 (-4.2A)F86 P 102 ( 3.0A)POP A1003 ( 3.5A)NoneNone | ||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 36PHE A 48VAL A 42 | 1.19A | None | |||
![]() | 1KIJ_B_NOVB444_2 (DNA GYRASE SUBUNIT B) | 7bv2 | NSP12 (SARS-CoV-2) | 3 / 3 | ASP A 418PHE A 859VAL A 848 | 1.47A | None |